The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,955 | -7,910 |
| Depreciation and amortization | 164 | 270 |
| Provision for inventory obsolescence | 33 | 172 |
| Loss on disposal of property and equipment | -19 | 0 |
| Stock-based compensation | 530 | 971 |
| Allowance for credit losses | 130 | 156 |
| Non-cash lease expense | 20 | 48 |
| Non-cash interest expense | 242 | 472 |
| Trade receivables | 1,836 | -4,413 |
| Prepaid expenses and other assets | 425 | -434 |
| Inventories | 865 | 720 |
| Accounts payable | 328 | 182 |
| Accrued expenses and other liabilities | 79 | -423 |
| Net cash used in operating activities | -3,536 | -1,935 |
| Purchases of property and equipment | 519 | 320 |
| Net cash used in investing activities | -519 | -320 |
| Proceeds from stock option exercises | 49 | - |
| Repayment of finance lease liabilities | 4 | 10 |
| Contributions from non-controlling interest | 0 | 60 |
| Net cash provided by (used in) financing activities | 45 | 50 |
| Effect of exchange rates on cash | -156 | -235 |
| Net change in cash and cash equivalents | -4,166 | -2,440 |
| Cash and cash equivalents at beginning of period | 31,741 | - |
| Cash and cash equivalents at end of period | 25,135 | - |
Apyx Medical Corp (APYX)
Apyx Medical Corp (APYX)